Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults - CAM 80124

Description
Hematopoietic cell transplantation (HCT) is an established treatment for certain hematologic malignancies and has been investigated for a variety of adult solid tumors. Interest continues in exploring nonmyeloablative allogeneic HCT (allo-HCT) for a graft-versus-tumor effect of donor-derived T-cells in metastatic solid tumors.

Summary of Evidence
Autologous Hematopoietic Cell Transplantation
For individuals who have adult soft tissue sarcomas who receive autologous HCT, the evidence includes a RCT, a number of phase 2 single-arm studies (some of which have been summarized in a systematic review), and a retrospective registry study. Relevant outcomes are overall survival (OS), disease-specific survival, and treatment-related mortality and morbidity. Although a small phase 2 RCT reported longer survival for patients treated with autologous HCT than with standard chemotherapy, this trial did not show a survival benefit with HCT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have small cell lung cancer who receive autologous HCT, the evidence includes several RCTs, and systematic reviews of these studies. Relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. Studies have not reported increased OS for patients with small-cell lung cancer treated with autologous HCT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Allogeneic Hematopoietic Cell Transplantation
For individuals who have renal cell carcinoma, colorectal cancer , pancreatic cancer, or nasopharyngeal cancer who receive allo-HCT, the evidence includes small single-arm series. Relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. The evidence for allo-HCT to treat renal cell carcinoma, colorectal cancer, pancreatic cancer, and nasopharyngeal cancer has been limited to small case series. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information
Not applicable

Background
HEMATOPOIETIC CELL TRANSPLANTATION
Hematopoietic cell transplantation (HCT) is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT [allo-HCT]). They can be harvested from bone marrow, peripheral blood, or from umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically "naive" and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in detail in evidence review 70150.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is critical for achieving a good outcome of allo-HCT. Compatibility is established by typing of human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

Conditioning for HCT
Conventional Conditioning
The conventional ("classical") practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is a result of a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect mediated by non-self-immunologic effector cells that develop after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects that include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immunosuppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility to opportunistic infections. The immune reactivity between donor T cells and malignant cells that is responsible for the GVM effect also leads to acute and chronic GVHD.

The success of autologous HCT is predicated on the ability of cytotoxic chemotherapy with or without radiation to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-Intensity Conditioning for Allo-HCT
Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is to reduce disease burden but also to minimize as much as possible associated treatment-related morbidity and nonrelapse mortality (NRM) in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative, to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this evidence review, RIC will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

HCT IN SOLID TUMORS IN ADULTS
HCT is an established treatment for certain hematologic malignancies. Its use in solid tumors is less well established, although it has been investigated for a variety of solid tumors. With the advent of nonmyeloablative allogeneic transplant, interest has shifted to exploring the generation of alloreactivity to metastatic solid tumors via a graft-versus-tumor effect of donor-derived T cells.¹

HCT as a treatment for ovarian cancer, germ cell tumors, ependymoma, or malignant glioma is addressed separately (evidence reviews 80123, 80135, and 80128, respectively). HCT as a treatment for breast cancer is not addressed. This evidence review collectively addresses other solid tumors of adults for which HCT has been investigated, including lung cancer, malignant melanoma, tumors of the gastrointestinal tract (affecting the colon, rectum, pancreas, stomach, esophagus, gallbladder, or bile duct), male and female genitourinary systems (e.g., renal cell carcinoma, prostate cancer, cervical cancer, uterine cancer, fallopian tube cancer), tumors of the head and neck, soft tissue sarcoma, thyroid tumors, tumors of the thymus, and tumors of unknown primary origin.

Regulatory Status
The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Related Policies
70150 Placental and Umbilical Cord Blood as a Source of Stem Cells
80123 Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer
80128 Hematopoietic Cell Transplantation for CNS Embryonal Tumors and Ependymoma
80134 Hematopoietic Cell Transplantation for Solid Tumors of Childhood
80135 Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Policy
Autologous or allogeneic hematopoietic cell transplant is investigational and/or unproven and therefore considered NOT MEDICALLY NECESSARY for the following malignancies in adults:

Lung cancer, any histology
Colon cancer
Rectal cancer
Pancreas cancer
Stomach cancer
Esophageal cancer
Gall bladder cancer
Cancer of the bile duct
Renal cell cancer
Cervical cancer
Uterine cancer
Cancer of the fallopian tubes
Prostate cancer
Nasopharyngeal cancer
Paranasal sinus cancer
Neuroendocrine tumors
Soft tissue sarcomas
Thyroid tumors
Tumors of the thymus
Tumors of unknown primary origin
Malignant melanoma

Policy Guidelines
None

Benefit Application
BlueCard/National Account Issues
The following considerations may supersede this policy:

State mandates requiring coverage for autologous bone marrow transplantation offered as part of clinical trials of autologous bone marrow transplantation approved by the National Institutes of Health (NIH).
Some plans may participate in voluntary programs offering coverage for patients participating in NIH-approved clinical trials of cancer chemotherapies, including autologous bone marrow transplantation.
Some contracts or certificates of coverage (e.g., FEP) may include specific conditions in which autologous bone marrow transplantation would be considered eligible for coverage.

Rationale
Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Autologous Hematopoietic Cell Transplantation in Solid Tumors
Adult Soft Tissue Sarcomas
Clinical Context and Therapy Purpose
The purpose of autologous hematopoietic cell transplantation (HCT) is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with soft tissue sarcomas.

The question addressed in this evidence review is: Does autologous HCT improve the net health outcome for patients with soft tissue sarcomas?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults with soft tissue sarcomas.

Interventions
The therapy being considered is autologous HCT.

Comparators
Comparators of interest include the standard of care.

Outcomes
The general outcomes of interest are overall survival (OS), disease-specific survival, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to monitor relevant outcomes.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

Review of Evidence
The prognosis of patients with unresectable or metastatic soft tissue sarcomas is poor, with a median survival of 1 year and a 5-year survival estimate of 15%.² A variety of single-agent and combination regimens are used for treatment, with targeted therapies available for some subtypes.³Based on initial observations that patients who achieved complete remission (CR) had longer survival, several phase 1 and 2 trials using autologous HCT were conducted in the 1990s in an attempt to improve outcomes.⁴ These trials were composed of small numbers of patients (range, 2 to 55 patients), yielding overall response rates (ORRs) from 20% to 65%, with CR ranging from 10% to 43%. The longest reported 5-year progression-free survival (PFS) rate was 21%, and the 5-year OS rate was 32%.⁴ One study of 21 patients with soft tissue sarcoma showed a PFS and OS benefit only in patients with no evidence of disease prior to HCT.⁵ In another phase 2 study, 21 (38%) of 55 patients responded to doxorubicin-based induction chemotherapy, but estimated 5-year OS did not differ statistically between those who did (14%) and did not (3%) receive an autologous HCT (p = .08 ).⁶

Systematic Reviews
In 2017, a Cochrane systematic review evaluated the use of autologous HCT following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.⁷ One RCT assessing 83 patients was identified.⁸ In the RCT, OS did not differ statistically between autologous HCT following high-dose and standard-dose chemotherapy (hazard ratio, 1.26; 95% confidence interval [CI], 0.70 to 2.29; p = .44), and the point estimate for survival at 3 years was 32.7% compared with 49.4%. Peinemann and Labeit (2014) conducted another systematic review that included an RCT (described above) and 61 single-arm studies.^9, The pooled risk of treatment-related mortality across 61 single-arm studies was 15 (5.1%) of 294 patients.

Randomized Controlled Trials
A 2019 RCT evaluated the use of autologous HCT following high-dose chemotherapy for Ewing Sarcoma in patients younger than 50 years of age with only pulmonary or pleural metastases.¹⁰ The median age of patients was 14.2 years (range, 1.0 to 47.8 years). Induction chemotherapy for all patients consisted of 6 chemotherapy courses combining vincristine, ifosfamide, doxorubicin, and etoposide and 1 course of vincristine, dactinomycin, and ifosfamide. Patients were then randomized to receive either high-dose chemotherapy with autologous HCT without whole-lung irradiation (n = 144) or standard-dose chemotherapy with whole-lung irradiation (n = 143). Median follow-up was 8.1 years. No significant differences in survival outcomes between treatment groups were observed. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for standard-dose chemotherapy and high-dose chemotherapy with autologous HCT, respectively (hazard ratio, 0.79; 95% CI, 0.56 to 1.10; p = .16). The hazard ratio for OS was 1.00 (95% CI, 0.70 to 1.44; p = .99). Four patients died as a result of toxicity from high-dose chemotherapy with autologous HCT, and none died after standard-dose chemotherapy. Investigators concluded there is no clear benefit from high-dose chemotherapy with autologous HCT compared with standard-dose chemotherapy.

Nonrandomized Studies
A small number of studies not included in the Cochrane review have described outcomes after HCT for soft tissue sarcoma. Kasper et al. (2010) reported the results of a prospective, single-institution phase 2 study that enrolled 34 patients with advanced and/or metastatic soft tissue sarcoma.¹¹ After 4 courses of chemotherapy, 9 patients with at least a partial response underwent high-dose chemotherapy and autologous HCT. All other patients continued chemotherapy for 2 more cycles. Median PFS for patients treated with HCT was 11.6 months (range, 8 to 15 months) and 5.6 months for patients treated with standard chemotherapy (p = .047); median OS for the 2 groups was 23.7 months (range, 12 to 34 months) and 10.8 months (range 0 to 39 months; p = .027), respectively.

Hartmann et al. (2013) reported on results from a phase 2 study of high-dose chemotherapy with ifosfamide, carboplatin, and etoposide followed by peripheral blood stem cell transplantation in patients with grade 2 or 3 histologically proven soft tissue sarcoma considered unresectable or marginally resectable.¹² After a median follow-up of 50 months (range, 26 to 120 months) in surviving patients, median PFS for all patients was 21 months (range, 1 to 94 months) and median OS was 37 months (range, 3 to 120 months), corresponding to 5-year PFS and OS rates of 39% and 48%, respectively.

A 2020 registry study retrospectively evaluated the effectiveness of autologous HCT in the treatment of soft tissue sarcoma using data from the European Society for Blood and Marrow Transplantation database between 1996 and 2016 (N = 338).¹³ The PFS and OS were 8.3 and 19.8 months, respectively. The PFS and OS at 5 years were 13% and 25%, respectively. Predictors of favorable benefit with HCT were younger age, better remission status before transplantation, and melphalan-based preparative regimens. The authors concluded that autologous HCT should not be performed on patients with soft tissue sarcoma in routine clinical practice without further investigation.

Section Summary: Adult Soft Tissue Sarcomas
Overall, 2 RCTs, several, small phase 2 studies, and a retrospective registry study have reported outcomes after autologous HCT in adults with soft tissue sarcoma. Although 1 small phase 2 study reported longer survival for patients treated with HCT than with standard chemotherapy, the RCT did not show an overall survival benefit with autologous HCT. An RCT from 2019 also showed no survival benefits with autologous HCT.

Small Cell Lung Cancer
Clinical Context and Therapy Purpose
The purpose of autologous HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with small cell lung cancer (SCLC).

The question addressed in this evidence review is: Does autologous HCT improve the net health outcome for patients with SCLC?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults with SCLC.

Interventions
The therapy being considered is autologous HCT.

Comparators
Comparators of interest include the standard of care.

Outcomes
The general outcomes of interest are OS, disease-specific survival, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to monitor relevant outcomes.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Systematic Reviews
The interest in treating SCLC with autologous HCT stems from the extremely high chemosensitivity and poor prognosis of this tumor type. Jiang et al. (2009) performed a meta-analysis of English-language studies through October 2008 using intensified chemotherapy with autologous hematopoietic progenitors to treat SCLC.¹⁴ The meta-analysis consisted of 5 RCTs (3 phase 3 trials, 2 phase 2), with a total of 641 patients. Reviewers found no significant increase in the odds ratio for response rate with autologous transplant versus control chemotherapy (odds ratio, 1.29; 95% CI, 0.87 to 1.93; p = .206). No statistically significant increase in OS was seen among the autologous transplant patients compared with control regimens (hazard ratio, 0.94; 95% CI, 0.80 to 1.10; p = .432). Reviewers concluded that current evidence did not support the use of intensified chemotherapy and autologous HCT for treating SCLC.

Randomized Controlled Trials
A phase 3 trial randomized 318 patients with SCLC to standard chemotherapy or to HCT.¹⁵ No statistically significant difference in response rates was seen between the 2 groups (response rate, 80% in standard arm group versus 88% in the HCT group; difference, 8%; 95% CI, -1% to 17%; p = .09). There was no statistically significant difference in OS between groups, with a median OS of 13.9 months in the standard arm (95% CI, 12.1 to 15.7 months) and 14.4 months in the HCT arm (95% CI, 13.1 to 15.4 months; p = .76). One smaller, randomized study and several single-arm studies of HCT and autologous HCT for SCLC are summarized in a 2007 review article.^16, Overall, most of the data from these studies, including the randomized study, showed no increase in OS with autologous HCT.

Section Summary: Small Cell Lung Cancer
Treatment of SCLC with autologous HCT has been studied in a meta-analysis, RCTs, and small series. None of these studies showed a survival benefit with autologous HCT.

Other Tumors
Review of Evidence
Uncontrolled pilot studies of autologous HCT for patients with refractory urothelial carcinoma¹⁷ and recurrent or advanced nasopharyngeal carcinoma¹⁸ have not demonstrated adequate evidence of improved outcomes to alter previous conclusions. In a 2014 small series (n = 8) of bilateral retinoblastoma survivors with secondary osteosarcoma, 2 patients (of 7 treated with multimodal chemotherapy) received high-dose chemotherapy with autologous peripheral blood stem cell support.¹⁹ The 2 HCT-treated patients were alive with no evidence of disease at 33.4 and 56.4 months of follow-up.

Allogeneic Hematopoietic Cell Transplantation in Solid Tumors
The evidence base for the treatment of patients with other types of solid tumors (refractory urothelial carcinoma, recurrent or advanced nasopharyngeal carcinoma, and secondary osteosarcoma) using allogeneic hematopoietic cell transplantation (allo-HCT) consists of single-case reports and small series.^1,20,21

Renal Cell Carcinoma
Clinical Context and Therapy Purpose
The purpose of allo-HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with renal cell carcinoma (RCC).

The question addressed in this evidence review is: Does allo-HCT improve the net health outcome for patients with RCC?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults with RCC.

Interventions
The therapy being considered is allo-HCT.

Comparators
Comparators of interest include the standard of care.

Outcomes
The general outcomes of interest are OS, disease-specific survival, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to monitor relevant outcomes.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Metastatic RCC has an extremely poor prognosis, with a median survival of less than 1 year and 5-year survival of approximately 12%.22,RCC is relatively resistant to chemotherapy, but is susceptible to immune therapy. Interleukin-2 and/or interferon-α have induced responses and long-term PFS rates in 4% to 15% of patients.²¹ In addition, 10 targeted therapies are approved by the U.S. Food and Drug Administration for the treatment of advanced RCC: sunitinib, sorafenib, pazopanib, axitinib, temsirolimus, everolimus, bevacizumab, cabozantinib, lenvatinib, and tivozanib.²² Based on the susceptibility of RCC to immune therapies, the immune-based strategy of a graft-versus-tumor effect possible with an allogeneic transplant has led to an interest in its use in RCC. Childs et al. (2000) published on the first series of patients with RCC treated with nonmyeloablative allo-HCT.²³ The investigators showed tumor regression in 10 (53%) of 19 patients with cytokine-refractory, metastatic RCC who received a human leukocyte antigen (HLA)-identical sibling allo-HCT. Three patients had a CR and remained in remission 16, 25, and 27 months after transplant. Four of 7 patients with a partial response were alive without disease progression 9 to 19 months after transplantation. Other pilot trials have demonstrated the graft-versus-tumor effect of allo-HCT in metastatic RCC, but most have not shown as high a response rate. Overall response rates in these pilot trials have been approximately 25%, with CR rates of approximately 8%.²⁰ Prospective, randomized trials are needed to assess the net impact of this technique on the survival of patients with cytokine-refractory RCC.²⁰

Bregni et al. (2009) assessed the long-term benefit of allografting in 25 patients with cytokine-refractory metastatic RCC who received reduced-intensity conditioning (RIC) with allo-HCT from a sibling who was HLA-identical.²⁴ All patients received the same conditioning regimens. Response to allograft was available in 24 patients, with a CR in 1 patient and partial response in 4 patients. Twelve patients had a minor response or stable disease, and 7 had progressive disease. The ORR (complete plus partial) was 20%. Six patients died because of transplant-related mortality. Median survival was 336 days (range, 12 to 2332+ days). The 1-year OS rate was 48% (95% CI, 28% to 68%) and the 5-year OS rate was 20% (95% CI, 4% to 36%). The authors concluded that allografting can induce long-term disease control in a small fraction of cytokine-resistant patients with RCC, but that with the availability of novel targeted therapies for RCC, future treatment strategies should consider incorporating these therapies into the transplant regimen.

Section Summary: Allogeneic Hematopoietic Cell Transplantation in Renal Cell Carcinoma
Evidence on the use of allo-HCT for RCC is based on multiple case series. In the absence of RCTs, current evidence is insufficient to conclude whether allo-HCT results in improved OS among RCC patients.

Colorectal Cancer
Clinical Context and Therapy Purpose
The purpose of allo-HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with colorectal cancer (CRC).

The question addressed in this evidence review is: Does allo-HCT improve the net health outcome for patients with CRC?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults with CRC.

Interventions
The therapy being considered is allo-HCT.

Comparators
Comparators of interest include the standard of care.

Outcomes
The general outcomes of interest are OS, disease-specific survival, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to monitor relevant outcomes.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Aglietta et al. (2009) reported on their experience with 39 patients with metastatic CRC who underwent RIC allo-HCT between 1999 and 2004 at 9 European Group for Blood and Marrow Transplantation centers.²⁵ Patients were treated with 1 of 5 RIC regimens. Endpoints assessed were an achievement of mixed chimerism, the incidence of graft-versus-host disease (GVHD), treatment-related mortality, toxicities, OS, and time to treatment failure (in patients who responded to therapy). Patient population characteristics were heterogeneous; pretransplant disease status was a partial response in 2 patients, stable disease in 6 patients, and progressive disease in 31. Thirty-eight (97%) patients had previous treatment, some with only chemotherapy and others with surgery, chemotherapy, or both. After the transplant, tumor responses were complete and partial in 2% and 18% of patients, respectively, and 26% of patients had stable disease, for overall disease control in 46% of patients. Transplant-related mortality was 10%. Median overall follow-up was 202 days (range, 6 to 1020 days), after which time 33 patients had died and 6 were still alive. Tumor progression was the cause of death in 74% of patients. An assessment of the OS of patients was performed after stratifying by potential prognostic factors. Achievement of response after transplantation was associated with a difference in OS, with the 18 patients who had a response having a median OS of approximately 400 days versus approximately 120 days for those who had no response (p < .001). The authors concluded the allo-HCT approach should be reserved for patients with a partial response or stable disease after second-line therapy for metastatic CRC and that second-generation clinical trials in these patients would be warranted.

Section Summary: Allogeneic Hematopoietic Cell Transplantation in Colorectal Cancer
Evidence on the use of allo-HCT for CRC is based on case series. In the absence of RCTs, current evidence is insufficient to conclude whether allo-HCT improves OS among CRC patients.

Pancreatic Cancer
Clinical Context and Therapy Purpose
The purpose of allo-HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with pancreatic cancer.

The question addressed in this evidence review is: Does allo-HCT improve the net health outcome for patients with pancreatic cancer?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults with pancreatic cancer.

Interventions
The therapy being considered is allo-HCT.

Comparators
Comparators of interest include the standard of care.

Outcomes
The general outcomes of interest are OS, disease-specific survival, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to monitor relevant outcomes.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Kanda et al. (2008) reported on the efficacy of RIC allo-HCT for advanced pancreatic cancer in 22 patients from 3 transplantation centers in Japan.²⁶ RIC regimens differed across centers, and the patient population was fairly heterogeneous, with 15 patients having metastatic disease and 7 having locally advanced disease. All but 1 patient received chemotherapy of various combinations before a transplant, and 10 patients received localized radiotherapy. After allo-HCT, 1 patient achieved CR, 2 had a partial response, 2 had a minor response, and 8 had stable disease, with an ORR of 23%. Median survival was 139 days, and the major cause of death was tumor progression (median duration of survival in advanced pancreatic cancer in the nontransplant setting is less than 6 months, even in patients treated with gemcitabine). Only 1 patient survived longer than 1 year after transplantation. The authors concluded that tumor response was observed in 25% of patients with advanced pancreatic cancer who underwent allo-HCT and that the response was not durable. However, based on their observation of a relationship between longer survival and the infusion of a higher number of CD34-positive cells or the development of chronic GVHD, the authors recommended additional study to evaluate the immunologic effect on pancreatic cancer.

Abe et al. (2009) reported on outcomes for 5 patients with chemotherapy-resistant, unresectable pancreatic adenocarcinoma who received nonmyeloablative conditioning with allo-HCT.²⁷ Median age was 54 years (range, 44 to 62 years). All patients had advanced disease, either with metastases or peritonitis, and had received at least 1 course of chemotherapy including gemcitabine. After allo-HCT, tumor response was only observed in 2 patients; 1 had complete disappearance of the primary tumor and the other had a 20% reduction in tumor size; the remaining patients had progressive disease (n = 2) or stable disease (n = 1). Four patients died of progressive disease (median survival, 96 days; range, 28 to 209 days posttransplant). One patient died at day 57 secondary to rupture of the common bile duct from rapid tumor regression. The authors concluded that findings showed a graft-versus-tumor effect, but to obtain durable responses, an improved conditioning regimen and new strategies to control tumor growth after nonmyeloablative allo-HCT would be needed.

Omazic et al. (2017) reported on outcomes for 2 patients who received allo-HCT from HLA-identical sibling donors following resection of pancreatic ductal adenocarcinoma.²⁸ These patients were compared with 6 controls who underwent radical surgery for pancreatic ductal adenocarcinoma but did not receive HCT. Both patients receiving HCT were tumor-free after 9 years following diagnosis, whereas all the patients in the control group died within 4 years of diagnosis.

Section Summary: Allogeneic Hematopoietic Cell Transplantation in Pancreatic Cancer
Evidence on the use of allo-HCT for pancreatic cancer is based on multiple case series and a small comparative study. In the absence of RCTs, current evidence is insufficient to conclude whether allo-HCT improves OS among pancreatic cancer patients.

Nasopharyngeal Cancer
Clinical Context and Therapy Purpose
The purpose of allo-HCT is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with nasopharyngeal cancer.

The question addressed in this evidence review is: Does allo-HCT improve the net health outcome for patients with nasopharyngeal cancer?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is adults with nasopharyngeal cancer.

Interventions
The therapy being considered is allo-HCT.

Comparators
Comparators of interest include the standard of care.

Outcomes
The general outcomes of interest are OS, disease-specific survival, treatment-related mortality, and treatment-related morbidity.

Follow-up over months to years is of interest to monitor relevant outcomes.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Toh et al. (2011) reported on outcomes of a phase 2 trial of 21 patients with pretreated metastatic nasopharyngeal cancer.²⁹ Median patient age was 48 years (range, 34 to 57 years), and patients had received a median of 2 previous chemotherapy regimens (range, 1 to 8 regimens). All patients had extensive metastases. Patients underwent a nonmyeloablative allo-HCT with sibling allografts. Seven (33%) patients showed a partial response and 3 (14%) achieved stable disease. Four patients were alive at 2 years, and 3 showed prolonged disease control of 344, 525, and 550 days. After a median follow-up of 209 days (range, 4 to 1147 days), the median PFS was 100 days (95% CI, 66 to 128 days) and the median OS was 209 days (95% CI, 128 to 236 days). One- and 2-year OS rates were 29% and 19%, respectively, comparable to the median 7- to 14-month OS rates reported in the literature for metastatic nasopharyngeal patients treated with salvage chemotherapy without HCT.

Section Summary: Allogeneic Hematopoietic Cell Transplantation in Nasopharyngeal Cancer
Evidence on the use of allo-HCT for nasopharyngeal cancer is based on a phase 2 trial. In the absence of RCTs, current evidence is insufficient to conclude whether allo-HCT improves OS among nasopharyngeal cancer patients.

Mixed Tumor Types
Review of Evidence
Omazic et al. (2016) reported on long-term follow-up for 61 patients with a variety of solid tumor types considered incurable with conventional therapies who were treated with allo-HCT from 1999 to 2012.³⁰ Tumors included metastatic renal carcinoma (n = 22), cholangiocarcinoma (n = 17), colon cancer (n = 15), prostate cancer (n = 3), pancreatic adenocarcinoma (n = 3), and breast cancer (n = 1). Most patients (n = 59) had undergone surgical debulking of the primary tumor, and 31 patients had previously undergone additional therapy with cytotoxic chemotherapy, radiotherapy, or immunotherapy. Conditioning was myeloablative in 23 patients, reduced-intensity in 36 patients, and nonmyeloablative in 2 patients. Over a median follow-up of 8 years, OS rates at 5 and 10 years were 15% and 9%, respectively.

Summary of Evidence
Autologous Hematopoietic Cell Transplantation
For individuals who have adult soft tissue sarcomas who receive autologous HCT, the evidence includes 2 RCTs, a number of phase 2 single-arm studies (some of which have been summarized in a systematic review), and a retrospective registry study. Relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. Although a small phase 2 RCT reported longer survival for patients treated with autologous HCT than with standard chemotherapy, this trial did not show an overall survival benefit with HCT. An RCT from 2019 also showed no survival benefits with autologous HCT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in Supplemental Information if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network
Current National Comprehensive Cancer Network guidelines (2021 ) on the tumors addressed in this evidence review do not discuss hematopoietic cell transplantation (HCT) as a treatment option.³¹

American Society for Blood and Marrow Transplantation
In 2015, the American Society for Blood and Marrow Transplantation (now referred to as the American Society for Transplantation and Cellular Therapy) issued guidelines related to indications for autologous and allogeneic HCT.³²The guidelines were updated in 2020.³³The tumors addressed herein for which the society has provided recommendations are listed in Table 1.

Table 1. Recommendations for Use of Autologous and Allogeneic Hematopoietic Cell Transplantation

Condition	Treatment Option	2015 Recommendation	2020 Recommendation
Ewing sarcoma, high-risk	Allogeneic HCT	Not generally recommended	Developmental
	Autologous HCT	Standard of care, clinical evidence available	Standard of care, clinical evidence available
Renal cancer, metastatic	Allogeneic HCT	Developmental	Developmental
	Autologous HCT	Not generally recommended	Not generally recommended

HCT: hematopoietic cell transplantation.

U.S. Preventive Services Task Force Recommendations
Not applicable

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing
NCT04530487	Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults	40	May 2025
NCT04937842	Efficacy and Safety of Radiotherapy or Chemotherapy Combined with Microtransplantation in the Treatment of Advanced and Relapsed Solid Tumors	60	May 2025
NCT01505569	Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patientswith High Risk or Relapsed Solid or CNS Tumors	20	March 2024

NCT: national clinical trial.

References

Carnevale-Schianca F, Ricchiardi A, Capaldi A, et al. Allogeneic hemopoietic stem cell transplantation in solid tumors. Transplant Proc. Jul-Aug 2005; 37(6): 2664-6. PMID 16182778
American Society of Clinical Oncology (ASCO). Sarcoma, Soft Tissue: Statistics. https://www.cancer.net/cancer-types/sarcoma-soft-tissue/statistics. Updated February 2021. Accessed December 1, 2021.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 2.2021. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed December 2, 2021.
Pedrazzoli P, Ledermann JA, Lotz JP, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol. Oct 2006; 17(10): 1479-88. PMID 16547069
Kasper B, Dietrich S, Mechtersheimer G, et al. Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. Oncology. 2007; 73(1-2): 58-64. PMID 18334832
Schlemmer M, Wendtner CM, Falk M, et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology. 2006; 71(1-2): 32-9. PMID 17344669
Peinemann F, Enk H, Smith LA. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas. Cochrane Database Syst Rev. Apr 13 2017; 4: CD008216. PMID 28407197
Bui-Nguyen B, Ray-Coquard I, Chevreau C, et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol. Mar 2012; 23(3): 777-784. PMID 21652583
Peinemann F, Labeit AM. Autologous haematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas: a Cochrane systematic review*. BMJ Open. Jul 29 2014; 4(7): e005033. PMID 25079925
Dirksen U, Brennan B, Le Deley MC, et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. Dec 01 2019; 37(34): 3192-3202. PMID 31553693
Kasper B, Scharrenbroich I, Schmitt T, et al. Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. Bone Marrow Transplant. Jul 2010; 45(7): 1234-8. PMID 19935728
Hartmann JT, Horger M, Kluba T, et al. A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas. Invest New Drugs. Dec 2013; 31(6): 1592-601. PMID 24091981
Heilig CE, Badoglio M, Labopin M, et al. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open. Oct 2020; 5(5): e000860. PMID 33097652
Jiang J, Shi HZ, Deng JM, et al. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature. Lung Cancer. Aug 2009; 65(2): 214-8. PMID 19118919
Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst. May 04 2005; 97(9): 666-74. PMID 15870437
Crivellari G, Monfardini S, Stragliotto S, et al. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. Oncologist. Jan 2007; 12(1): 79-89. PMID 17227903
Nishimura M, Nasu K, Ohta H, et al. High dose chemotherapy for refractory urothelial carcinoma supported by peripheral blood stem cell transplantation. Cancer. Nov 01 1999; 86(9): 1827-31. PMID 10547557
Airoldi M, De Crescenzo A, Pedani F, et al. Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma. Head Neck. Sep 2001; 23(9): 799-803. PMID 11505492
Lee JA, Choi SY, Kang HJ, et al. Treatment outcome of osteosarcoma after bilateral retinoblastoma: a retrospective study of eight cases. Br J Ophthalmol. Oct 2014; 98(10): 1355-9. PMID 24795337
Imanguli MM, Childs RW. Hematopoietic stem cell transplantation for solid tumors. Update Cancer Ther. 2006;1(3):343-352.
Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol. May 2008; 5(5): 256-67. PMID 18398414
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: kidney cancer. Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed December 1, 2021.
Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. Sep 14 2000; 343(11): 750-8. PMID 10984562
Bregni M, Bernardi M, Servida P, et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant. Aug 2009; 44(4): 237-42. PMID 19234510
Aglietta M, Barkholt L, Schianca FC, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant. Mar 2009; 15(3): 326-35. PMID 19203723
Kanda Y, Omuro Y, Baba E, et al. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. Bone Marrow Transplant. Jul 2008; 42(2): 99-103. PMID 18391987
Abe Y, Ito T, Baba E, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. Pancreas. Oct 2009; 38(7): 815-9. PMID 19696692
Omazic B, Ayoglu B, Lohr M, et al. A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. J Immunother. May 2017; 40(4): 132-139. PMID 28338506
Toh HC, Chia WK, Sun L, et al. Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. Bone Marrow Transplant. Apr 2011; 46(4): 573-9. PMID 20661236
Omazic B, Remberger M, Barkholt L, et al. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. Biol Blood Marrow Transplant. Apr 2016; 22(4): 676-681. PMID 26740375
National Comprehensive Cancer Network (NCCN). NCCN guidelines & clinical resources. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed December 5, 2021.
Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. Nov 2015; 21(11): 1863-1869. PMID 26256941
Kanate AS, Majhail NS, Savani BN, et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. Jul 2020; 26(7): 1247-1256. PMID 32165328
Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for STEM CELL Transplantation (Formerly 110.8.1) (110.23). Updated January 27, 2016; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId = 366. Accessed December 1, 2021.

Coding Section

Codes	Number	Description
CPT	38204	Management of recipient hematopoietic cell donor search and cell acquisition
	38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
	38206	; autologous
	38208	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing
	38209	; thawing of previously frozen harvest, with washing
	38210	; specific cell depletion with harvest, T-cell depletion
	38211	; tumor-cell depletion
	38212	; red blood cell removal
	38213	; platelet depletion
	38214	; plasma (volume) depletion
	38215	; cell concentration in plasma, mononuclear, or buffy coat layer
	38220	Bone marrow; aspiration only
	38220 (effective 1/1/2018)	Diagnostic bone marrowl aspiration(s)
	38221	; biopsy, needle or trocar
	38221 (effective 1/1/2018)	biopsy(ies) and aspiration(s)
	38222 (effective 1/1/2018)	biopsy(ies) and aspiration(s)
	38240	Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic
	38241	; autologous
ICD-9 Procedure	41.01	Autologous bone marrow transplant without purging
	41.02	Allogeneic bone marrow transplant with purging
	41.03	Allogeneic bone marrow transplant without purging
	41.04	Autologous hematopoietic stem-cell transplant without purging
	41.05	Allogeneic hematopoietic stem-cell transplant without purging
	41.06	Cord blood stem-cell transplant
	41.07	Autologous hematopoietic stem-cell transplant with purging
	41.09	Autologous bone marrow transplant with purging
	41.91	Aspiration of bone marrow from donor for transplant
	99.79	Other therapeutic apheresis (includes harvest of stem cells)
ICD-9 DIAGNOSIS		Investigational for all codes
HCPCS	Q0083-Q0085	Chemotherapy administration code range
	J9000-J9999	Chemotherapy drugs code range
	S2150	Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, highdose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic, and emergency services)
ICD-10-CM (effective 10/01/15)		Investigational for all relevant diagnoses
	C11.0-C11.9	Malignant neoplasm of nasopharynx code range
	C15.3-C15.9	Malignant neoplasm of esophagus code range
	C16.0-C16.9	Malignant neoplasm of stomach code range
	C18.0-C18.9	Malignant neoplasm of colon code range
	C20	Malignant neoplasm of rectum
	C23	Malignant neoplasm of gallbladder
	C24.0-C24.9	Malignant neoplasm of other and unspecified parts of biliary tract code range
	C25.0-C25.9	Malignant neoplasm of pancreas code range
	C31.0-C31.9	Malignant neoplasm of accessory sinuses code range
	C34.00-C34.92	Malignant neoplasm of bronchus and lung code range
	C37	Malignant neoplasm of thymus
	C43.0-C43.9	Malignant melanoma of skin code range
	C46.1	Kaposi's sarcoma of soft tissue
	C53.0-C53.9	Malignant neoplasm of cervix uteri code range
	C54.0-C54.9	Malignant neoplasm of corpus uteri code range
	C55	Malignant neoplasm of uterus, part unspecified
	C57.00-C57.02	Malignant neoplasm of fallopian tube code range
	C61	Malignant neoplasm of prostate
	C64.0-C64.9	Malignant neoplasm of kidney, except renal pelvis code range
	C65.0-C65.9	Malignant neoplasm of renal pelvis code range
	C73	Malignant neoplasm of thyroid gland
	C7a.00-C7b.8	Malignant neuroendocrine tumors code range
	C80.1	Malignant (primary) neoplasm, unspecified
ICD-10-PCS (effective 10/01/15)		ICD-10-PCS codes are only used for inpatient services.
	30243G0, 30243X0, 30243Y0	Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list
	30243G1, 30243X1, 30243Y1	Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list
	07DQ0ZZ, 7DQ3ZZ, 07DR0ZZ, 7DR3ZZ, 07DS0ZZ, 07DS3ZZ	Surgical, lymphatic and hemic systems, extraction, bone marrow, code list
Type of Service	Therapy
Place of Service	npatient/Outpatient

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

History From 2014 Forward

07/07/2022	Annual review, no change to policy intent. Updating rationale and references
07/08/2021	Annual review, no change to policy intent. Updating description, rationale and references.
07/23/2020	Annual review, no change to policy intent. Updating rationale and references.
07/01/2019	Annual review, no change to policy intent. Updating description, rationale and references.
07/26/2018	Annual review, no change to policy intent. Updating rationale and references.
12/6/2017	Updating policy with 2018 coding. No other changes.
07/10/2017	Annual review, no change to policy intent. Updating entire policy to remove stem in relation to transplant in accordance with NCCN terminology. Also updating background, description, guidelines, regulatory status, rationale and references.
07/25/2016	Annual review, no change to policy intent. Updating background, description, rationale and references. Adding regulatory status.
07/29/2015	Annual review, no change to policy intent. Updated background, description, related policies, rationale and references. Added coding.
07/10/2014	Annual review. Updated rationale and references. Added related policies. No change to policy intent.

Policy List

Edit Policy

{{ navigationConstituentPage.title || 'Medical Policies' }}

Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults - CAM 80124